Cancer preventia

cancer-free future with cancer risk detection ahead of symptoms

simple • non-invasive • high accuracy

Cancer cells can be difficult to detect, especially in the early stages.

This is because:

Small in Size

Small in Size

Conventional imaging techniques may not be able to identify cancer cells in the early stages due to its small size.

Lack of Symptoms

Lack of Symptoms

In some cases, early stages of cancer may not exhibit noticeable symptoms, leading to delayed diagnosis. 

Similarity to Normal Cells

Similarity to Normal Cells

In the early stages, cancer cells resembles closely to healthy cells, making it challenging to identify.

Limitations of Screening Tests

Limitations of Screening Tests

Some cancers lack reliable and sensitive screening tests, further hindering early detection.

Location

Location

Depending on the location of the tumor, gaining access to assess the cancer cells without invasive procedures is challenging.

Heterogeneity

Heterogeneity

Tumors can contain a mix of cancer cells with various genetic mutations, making it extremely complex to target.

  • shape

    Small in Size

    Conventional imaging techniques may not be able to identify cancer cells in the early stages due to its small size.

  • shape

    Lack of Symptoms

    In some cases, early stages of cancer may not exhibit noticeable symptoms, leading to delayed diagnosis.

  • shape

    Similarity to Normal Cells

    In the early stages, cancer cells resembles closely to healthy cells, making it challenging to identify.

  • shape

    Limitations of Screening Tests

    Some cancers lack reliable and sensitive screening tests, further hindering early detection.

  • shape

    Location

    Depending on the location of the tumor, gaining access to assess the cancer cells without invasive procedures is challenging.

  • shape

    Heterogeneity

    Tumors can contain a mix of cancer cells with various genetic mutations, making it extremely complex to target.

Introducing a breakthrough "biological" Cancer Risk Assessment Test - N-NOSE®

Nematodes-100x100

What is N-Nose®?

N-NOSE® is a potent diagnostic tool that detects the risk of cancer, even at stage 1 or earlier with sensitivity of 86.3%. This allows individuals to take proactive measures at a much earlier stage at a much lower risk.

How does N-Nose® work?

Bodily fluids of cancer patients smell different to those of healthy individuals. With just a drop of urine, N-Nose® test screens the risk for 15 types of cancer using the highly sensitive smelling abilities of nematodes (C. elegans) – a type of microscopic roundworm. 

Nematodes (C. elegans) possess approximately 1,200 olfactory receptor genes, surpassing dogs, enabling them to detect minute odors undetectable by machines.

Healthy Urine Sample

Cancer Patient Sample

Why N-Nose®?

1

Non-invasive

Quick and easy test using a single drop of urine.

2

Accessible

Suitable for every individual aged 16 and above.​

For more information on the N-NOSE® technology: https://hbio.jp/en/dsc/archives1

Advantages of Early Detection of Cancer using

N-NOSE®

Increases Range of Treatment Options

Higher Success Rate of Treatment

Improves Recovery Time

Reduces Treatment Expenses

Testimonials

Book for your test now

Frequently Asked Questions

0